Scroll

danazol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	779	17230-88-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: danazol chronogyn danatrol danazolum danocrine danovaol danzol winobanin	A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. Molecular weight: 337.46 Formula: C22H27NO2 CLOGP: 3.75 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.26 ALOGS: -4.28 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

danazol
chronogyn
danatrol
danazolum
danocrine
danovaol
danzol
winobanin

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Molecular weight: 337.46
Formula: C22H27NO2
CLOGP: 3.75
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.26
ALOGS: -4.28
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	33.78 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	5.18 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15.71 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.31 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 21, 1976	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hereditary angioedema	172.87	21.95	43	2378	7519	63479082
Drug ineffective for unapproved indication	95.27	21.95	39	2382	34024	63452577
Angioedema	91.79	21.95	42	2379	47923	63438678
Swollen tongue	84.40	21.95	36	2385	34764	63451837
Dysphonia	79.65	21.95	38	2383	47576	63439025
Swelling face	66.57	21.95	37	2384	63438	63423163
Platelet count decreased	59.49	21.95	43	2378	116079	63370522
Product use in unapproved indication	54.76	21.95	49	2372	179031	63307570
Hypoperfusion	31.77	21.95	8	2413	1459	63485142
Drug ineffective	28.04	21.95	95	2326	1044670	62441931
Hypersensitivity	27.74	21.95	44	2377	292641	63193960
Bone marrow reticulin fibrosis	26.94	21.95	5	2416	216	63486385
Myelofibrosis	22.49	21.95	6	2415	1371	63485230
Drug intolerance	22.12	21.95	41	2380	308620	63177981

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coombs positive haemolytic anaemia	267.45	28.54	48	2395	924	34953564
Lymphadenitis	232.22	28.54	48	2395	1980	34952508
Haemolysis	193.33	28.54	54	2389	8040	34946448
Migraine	122.55	28.54	46	2397	17432	34937056
Hereditary angioedema	121.05	28.54	25	2418	1022	34953466
Hepatic enzyme increased	110.42	28.54	54	2389	39026	34915462
Infusion related reaction	97.58	28.54	55	2388	53002	34901486
Therapeutic product effect decreased	86.26	28.54	44	2399	34699	34919789
Myelofibrosis	68.46	28.54	17	2426	1594	34952894
Drug ineffective	58.03	28.54	109	2334	456642	34497846
Constipation	54.73	28.54	57	2386	136925	34817563
Myelodysplastic syndrome	49.57	28.54	25	2418	19183	34935305
Rhabdomyolysis	45.90	28.54	38	2405	68125	34886363
Neutropenia	43.47	28.54	54	2389	156724	34797764
Bone marrow reticulin fibrosis	31.30	28.54	6	2437	166	34954322
Platelet count decreased	29.59	28.54	39	2404	119678	34834810

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coombs positive haemolytic anaemia	272.39	21.66	48	4257	1082	79739001
Lymphadenitis	204.63	21.66	48	4257	4607	79735476
Hereditary angioedema	182.84	21.66	45	4260	5290	79734793
Haemolysis	169.31	21.66	51	4254	12761	79727322
Drug ineffective for unapproved indication	80.70	21.66	44	4261	51194	79688889
Migraine	72.94	21.66	50	4255	87443	79652640
Rhabdomyolysis	65.55	21.66	50	4255	103081	79637002
Swollen tongue	65.48	21.66	36	4269	42534	79697549
Angioedema	64.66	21.66	44	4261	75991	79664092
Drug ineffective	63.04	21.66	162	4143	1080751	78659332
Myelofibrosis	60.57	21.66	16	4289	2484	79737599
Platelet count decreased	58.86	21.66	62	4243	194602	79545481
Hepatic enzyme increased	56.71	21.66	59	4246	182551	79557532
Dysphonia	53.37	21.66	35	4270	56837	79683246
Swelling face	50.75	21.66	37	4268	71175	79668908
Bone marrow reticulin fibrosis	46.52	21.66	9	4296	341	79739742
Myelodysplastic syndrome	44.87	21.66	25	4280	30276	79709807
Product use in unapproved indication	41.71	21.66	59	4246	250300	79489783
Infusion related reaction	40.95	21.66	56	4249	230181	79509902
Therapeutic product effect decreased	37.20	21.66	45	4260	163818	79576265
Constipation	36.21	21.66	59	4246	282991	79457092
Immune thrombocytopenia	32.83	21.66	17	4288	17788	79722295
Neutropenia	31.54	21.66	56	4249	287654	79452429
Cushingoid	26.30	21.66	12	4293	9540	79730543
Mucosal haemorrhage	24.53	21.66	8	4297	2578	79737505
Hypoperfusion	24.37	21.66	8	4297	2631	79737452
Gingival bleeding	22.92	21.66	13	4292	16263	79723820
Splenomegaly	22.50	21.66	14	4291	20740	79719343
Thrombocytopenia	22.12	21.66	46	4259	265213	79474870

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XA01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Antigonadotropins and similar agents
FDA CS	M0001109	Androstanes
FDA MoA	N0000000146	Androgen Receptor Agonists
CHEBI has role	CHEBI:50751	anti-estrogenic drug
CHEBI has role	CHEBI:50837	oestrogen antagonist
CHEBI has role	CHEBI:176497	geroprotectors
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D006727	Hormone Antagonists
FDA EPC	N0000175824	Androgen

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Fibrocystic breast changes	indication	27431007	DOID:10354
Endometriosis	indication	129103003
Hereditary Angioedema Prevention	indication
Gynecomastia	off-label use	4754008	DOID:12698
Menorrhagia	off-label use	386692008
Precocious puberty	off-label use	400179000
Migraine	contraindication	37796009	DOID:6364
Chronic heart failure	contraindication	48447003
Intermenstrual bleeding - irregular	contraindication	64996003
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Mixed hyperlipidemia	contraindication	267434003
Pregnancy, function	contraindication	289908002
Thromboembolic disorder	contraindication	371039008
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	AGONIST			UNKNOWN	CHEMBL
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	AGONIST			WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.16	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.09	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.25	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.60	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	4.98	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.01	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.43	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.71	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	4.89	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	5.46	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.27	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.20	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.21	DRUG MATRIX
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN		Ki	5.29	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.52	DRUG MATRIX
Steryl-sulfatase	Enzyme	P08842	STS_HUMAN				WOMBAT-PK
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	8.20	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.05	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.24	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	4.99	DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		Ki	8.10	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	7.47	DRUG MATRIX

External reference:

ID	Source
4018233	VUID
N0000146564	NUI
D00289	KEGG_DRUG
258343	RXNORM
4018233	VANDF
C0010961	UMLSCUI
CHEBI:4315	CHEBI
QA1	PDB_CHEM_ID
CHEMBL1479	ChEMBL_ID
DB01406	DRUGBANK_ID
D003613	MESH_DESCRIPTOR_UI
28417	PUBCHEM_CID
6942	IUPHAR_LIGAND_ID
2556	INN_ID
N29QWW3BUO	UNII
3093	MMSL
4533	MMSL
605	MMSL
d00204	MMSL
002116	NDDF
126124009	SNOMEDCT_US
87881000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1368	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1368	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1369	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1369	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1392	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1392	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0633	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0633	CAPSULE	50 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0634	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0634	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0635	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0635	CAPSULE	200 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	42291-243	CAPSULE	200 mg	ORAL	ANDA	16 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	62135-475	CAPSULE	50 mg	ORAL	ANDA	11 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	62135-476	CAPSULE	100 mg	ORAL	ANDA	11 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	62135-477	CAPSULE	200 mg	ORAL	ANDA	11 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	68151-2298	CAPSULE	200 mg	ORAL	ANDA	21 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	71205-861	CAPSULE	100 mg	ORAL	ANDA	17 sections
Danazol	HUMAN PRESCRIPTION DRUG LABEL	1	71205-862	CAPSULE	200 mg	ORAL	ANDA	17 sections